Get the Stockscreener App
25.77
0.33%
0.09
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $25.77, with a volume of 17.24M.
It is up +0.33% in the last 24 hours and down -4.29% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$25.68
Open:
$25.79
24h Volume:
17.24M
Relative Volume:
0.44
Market Cap:
$146.82B
Revenue:
$63.32B
Net Income/Loss:
$7.52B
P/E Ratio:
19.76
EPS:
1.3043
Net Cash Flow:
$9.48B
1W Performance:
-2.03%
1M Performance:
-4.29%
6M Performance:
+1.00%
1Y Performance:
+15.64%
1-Day Range:
$25.75
$26.18
1-Week Range:
$25.60
$26.75
52-Week Range:
$21.97
$28.75
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.76 | 146.36B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
974.67 | 845.77B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
220.83 | 532.77B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
202.71 | 356.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
183.61 | 283.57B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
145.41 | 278.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | Argus | Hold → Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Underperform |
| Feb-20-26 | Initiated | Barclays | Underweight |
| Feb-12-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax? - 24/7 Wall St.
Pfizer vs Eli Lilly: Different Bets on Pharma M&A - Yahoo Finance
Is Most-Watched Stock Pfizer Inc. (PFE) Worth Betting on Now? - Yahoo Finance Singapore
Pfizer (PFE) Stock; Edges Lower as Investors Weigh Ongoing COVID Franchise Pressure - CoinCentral
Anaveon Announces Presentation of Positive ANV600 Clinical Data at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio - GlobeNewswire Inc.
Pfizer Stock Faces a Fresh COVID Patent Overhang as Investors Wait for Its Next Growth Act - TechStock²
Pfizer Advances Oncology Portfolio While Extending Vyndamax Cash Flow Visibility - Yahoo Finance
Pfizer (PFE) Surpasses Q1 Earnings Expectations, Reaffirms 2026 Sales Guidance - GuruFocus
Pfizer Viagra stock: what investors and health-conscious readers need to know in 2026 - Portal CNJ
What Pfizer (PFE)'s Earnings Beat, Reaffirmed Guidance and Oncology Wins Mean For Shareholders - simplywall.st
Great Hill Capital LLC's Pfizer Inc(PFE) Holding History - GuruFocus
GSA CAPITAL PARTNERS LLP's Pfizer Inc(PFE) Holding History - GuruFocus
Pfizer (PFE) Beats EPS Estimates, Reaffirms Full-Year Outlook - GuruFocus
Pfizer Inc. stock (US7170811035): Q1 2026 results and recent share price move - AD HOC NEWS
Opportunities to Drive Change in Alopecia Areata - Pfizer
Here is Why Pfizer (PFE) One of the Best High Volume Stocks to Invest In - Insider Monkey
Pfizer Inc (PFE) Shares Fall 3.0% -- What GF Score of 76 Tells I - GuruFocus
Pfizer Options Spot-On: On May 8th, 207.87K Contracts Were Traded, With 2.63 Million Open Interest - Moomoo
-3.15% for Pfizer stock as new share registration weighs on outlook - Traders Union
Novavax Inc stock (US66987V1098): Shares jump on Q1 beat and Pfizer deal momentum - AD HOC NEWS
Earnings recap: Airbnb, AMD, Shopify, Pfizer, Uber, Arm, Disney… - Proactive financial news
Novavax (NVAX) Soars After Earnings Beat And Pfizer Deal - StocksToTrade
Novavax Stock Jumps As Pfizer Deal Cash Puts Vaccine Turnaround Back In Focus - TechStock²
Pfizer Terminates Early-Stage Cancer Trial: What It Means for PFE Investors - TipRanks
Duavee by Pfizer, Inc - Pharmacy Times
Novavax Stock Jumps As Pfizer Deal And Q1 Beat Energize Traders - timothysykes.com
Assessing Pfizer’s (PFE) Valuation As Shares Hover Near Recent Levels - simplywall.st
Small Molecule Drug Discovery Market Is Going to Boom Rapidly | Pfizer Inc., Merck & Co., Inc., Novartis AG - openPR.com
PFE.DE Technical Analysis | Trend, Signals & Chart Patterns | PFIZER INC (FRA:PFE) - ChartMill
Is Pfizer’s 6.5% Dividend a Yield Trap? Q1 Results Put Speculation to Rest - NAI500
Judge Knocks Out Pfizer Partner's Vax Case Against GSK - Law360
Pfizer Options Spot-On: On May 7th, 299.38K Contracts Were Traded, With 2.62 Million Open Interest - Moomoo
Pfizer Ends Early-Stage Lymphoma Combo Trial, Trimming a Small Piece of Its Oncology Upside - TipRanks
Pfizer’s Next Lyme Shot: What a Fifth-Dose VLA15 Trial Signals for PFE Investors - TipRanks
Novavax, Inc. Stock Jumps: Why Pfizer’s Matrix-M Deal Drove a Surprise Q1 Revenue Beat - TechStock²
Inside the Pfizer CentreOne OSD Network - Contract Pharma
Analysts Conflicted on These Healthcare Names: Pfizer (PFE), Spyre Therapeutics (SYRE) and Adaptive Biotechnologies (ADPT) - The Globe and Mail
Is Pfizer Stock Worth Buying After a Q1 2026 Beat and Patent Win? - TIKR.com
Pfizer Works to Address Inequities in IBD Care - Pfizer
Pfizer's 6.5% Dividend Yield Looked Too Good to Be True -- but Management Just Silenced the Skeptics - Yahoo Finance
How Pfizer’s Q1 Beat, Oncology Wins and Patent Deals At Pfizer (PFE) Has Changed Its Investment Story - Yahoo Finance
Is It Time To Reconsider Pfizer (PFE) After Recent Share Price Rebound? - simplywall.st
Pfizer and Our CEO Albert Bourla Recognized by TIME, Fortune - Pfizer
CEO Albert Bourla Reflects on Pfizer’s Year of Bold Moves and Relentless Innovation in 2025 Annual Review - Pfizer
Pfizer To Go Ex-Dividend On May 8th, 2026 With 0.43 USD Dividend Per Share - Moomoo
AI in Healthcare? Pfizer, Anthropic, and Longevity Scientists Think It’s Critical - Yahoo Finance
Pfizer Earnings Call Highlights Growth Beyond COVID - The Globe and Mail
Interviews: How To Upskill In A Lockdown - Pfizer
Tunica-Biloxi Tribe receives grant from Pfizer to expand healthcare in Central Louisiana - WGNO
Novavax (NVAX) Finds a New Revenue Engine in Pfizer Licensing - AlphaStreet
Pfizer’s newer medicines carry more weight in Q1 - thestreet.com
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.04%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):